Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report.
Multiple myeloma patients with plasmablastic morphology of tumor cells and extramedullary presentation of disease often have an aggressive clinical course and resistance to chemotherapy. We describe a case of an elderly patient who presented with extramedullary, IgA-lambda-secreting multiple myeloma with plasmablastic features who demonstrated impressive clinical response to single-agent lenalidomide. This is the first description of a plasmablastic variety of multiple myeloma successfully treated with lenalidomide alone.
Sher
Taimur
T
Department of Medicine, Roswell Park Cancer Institute and the State University of New York, Buffalo, NY, USA.
Miller
Kena C
KC
Lee
Kelvin
K
Chanan-Khan
Asher
A
D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D010950:Plasma Cells / Q000187:drug effects / Q000473:pathology*; D012074:Remission Induction; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide